STOCK TITAN

LifeStance Health: TPG GP A reports 11.2% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

LifeStance Health Group, Inc. (LFST) is the subject of an amended ownership report naming TPG GP A, LLC, James G. Coulter and Jon Winkelried as each having shared voting and dispositive power over the same 42,458,592 common shares, reported as 11.2% of the class. TPG VIII Lynnwood Holdings Aggregation, L.P. directly holds those shares. The reported percentage is based on 378,190,724 common shares outstanding as of November 12, 2026.

Coulter and Winkelried disclaim beneficial ownership of the shares held by TPG VIII Lynnwood except to the extent of their pecuniary interests. Under a stockholders agreement with other holders, the parties agreed to vote shares to elect directors as set forth in the agreement. The reporting persons may be deemed to beneficially own those other holders’ shares or to constitute a group, and disclaim beneficial ownership except to the extent of any pecuniary interest.

Common shares with shared voting and dispositive power 42,458,592 shares The same position is reported for each reporting person; directly held by TPG VIII Lynnwood Holdings Aggregation, L.P.
Reported ownership 11.2% Percentage of the class reported by each reporting person.
Common shares outstanding 378,190,724 shares As of November 12, 2026; used as the basis for the reported ownership percentage.
shared voting power regulatory
"Shared voting power 42,458,592"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared dispositive power 42,458,592"
beneficial owner regulatory
"may be deemed to be the beneficial owner of the shares"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Stockholders Agreement regulatory
"entered into a Stockholders Agreement, dated as of June 9, 2021"
pecuniary interest regulatory
"except to the extent of their pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LFST shares did TPG GP A, James G. Coulter and Jon Winkelried report?

Each reported shared voting and dispositive power over 42,458,592 LFST common shares, or 11.2% of the class. The shares are directly held by TPG VIII Lynnwood Holdings Aggregation, L.P.; the same position is reported for each reporting person.

What is the LFST stockholders agreement’s effect on voting?

TPG VIII Lynnwood and certain other holders agreed to vote their common shares to elect directors as set forth in the agreement. The reporting persons may be deemed to beneficially own the other holders’ shares or to constitute a group, while disclaiming beneficial ownership except to the extent of any pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





53228F101

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage beneficial ownership set forth in response to Item 11 above is based on 378,190,724 shares of Common Stock ("Common Stock") outstanding as of November 12, 2026, as reported in the Prospectus Supplement filed by LifeStance Health Group, Inc. (the "Issuer") with the Securities and Exchange Commission (the "Commission") on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage beneficial ownership set forth in response to Item 11 above is based on 378,190,724 shares of Common Stock outstanding as of November 12, 2026, as reported in the Prospectus Supplement filed by the Issuer with the Commission on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage beneficial ownership set forth in response to Item 11 above is based on 378,190,724 shares of Common Stock outstanding as of November 12, 2026, as reported in the Prospectus Supplement filed by the Issuer with the Commission on November 10, 2026.


SCHEDULE 13G



TPG GP A, LLC
Signature:/s/ Matthew White
Name/Title:Matthew White / Vice President
Date:11/16/2026
COULTER, JAMES G
Signature:/s/ Gerald Neugebauer
Name/Title:Gerald Neugebauer on behalf of James G. Coulter (1)
Date:11/16/2026
WINKELRIED, JON
Signature:/s/ Gerald Neugebauer
Name/Title:Gerald Neugebauer on behalf of Jon Winkelried (2)
Date:11/16/2026

Comments accompanying signature: (1) Gerald Neugebauer is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Coulter on February 7, 2024 (SEC File No. 001-41617). (2) Gerald Neugebauer is signing on behalf of Mr. Winkelried pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Winkelried on February 7, 2024 (SEC File No. 001-41617).
Exhibit Information

Exhibit 1 Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.* * Incorporated herein by reference to the Agreement of Joint Filing by TPG Group Holdings (SBS) Advisors, Inc., TPG GP A, LLC, TPG Advisors VII, Inc., TPG Advisors VI, Inc., TPG Advisors VI-AIV, Inc., TPG Asia Advisors VI, Inc., David Bonderman, James G. Coulter, Jon Winkelried and Karl Peterson dated as of January 18, 2022, which was previously filed with the Commission as Exhibit 1 to Amendment No. 4 to Schedule 13D filed by TPG GP A, LLC, David Bonderman, James G. Coulter and Jon Winkelried on January 18, 2022 with respect to the shares of common stock of Allogene Therapeutics, Inc.

Keep reading